TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

24.
21.452 Jeha LE et al. Long term outcome of patients with West Nile virus infection. Infect Dis Clin Pract
2005;13:101-3.
21.453 Kalil AC et al. Use of interferon-α in patients with West Nile encephalitis: report of 2 cases. Clin Infect
Dis 2005;40:764-6.
21.454 Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis 2007;44:850-6.
21.455 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic
infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1-
207.
21.456 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of
opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009;
58(RR-11):1-167.
22A.1 Nigro G et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N
Engl J Med 2005;353:1350-62.
22A.2 Victor JC et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J
Med 2007;357:1685-95.
22A.3 Centers for Disease Control and Prevention (CDC). Prevention of hepatitis A through active or passive
immunization. Morb Mortal Wkly Rep 1999;48(RR-12):1-37.
22A.4 Sagliocca L et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a
randomised trial. Lancet 1999;353:1136-9.
22A.5 Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate
transmission of hepatitis B virus infection in the United States. Morb Mortal Wkly Rep 2006;55
(RR-16):1-33.
22A.6 Ranger-Rogez S et al. Hepatitis B mother to child transmission. Expert Rev Anti Infect Ther 2004;2:
133-45.
22A.7 Centers for Disease Control and Prevention (CDC). Recommendations for prevention and control of
hepatitis C virus (HCV) infection and HCV related chronic disease. Morb Mortal Wkly Rep 1998;47
(RR-19):1-39.
22A.8 Centers for Disease Control and Prevention (CDC). Updated U.S. Public Health Service guidelines
for the management of occupational exposures to HBV, HCV, and HIV and recommendations for
postexposure prophylaxis. Morb Mortal Wkly Rep 2001;50(RR-11):1-52.
22A.9 Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting.
Clin Microbiol Rev 2003;16:546-68.
22A.10 Sulkowski MS et al. Hepatitis C virus infection as an opportunistic disease in persons infected with
human immunodeficiency virus. Clin Infect Dis 2000;30(suppl. 1):S77-84.
22A.11 Jaeckel E et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-
7.
22A.12 National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention
(CDC). Cercopithecine herpesvirus 1 (B virus) infection resulting from ocular exposure. Available
at: http://www.cdc.gov/niosh/docs/99-100/pdfs/99-100.pdf. Accessed on August 27 th 2010.
22A.13 Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines,
2006. Morb Mortal Wkly Rep 2006;55(RR-11):1-94.
22A.14 Gupta R et al. Genital herpes. Lancet 2007;370:2127-37.
22A.15 Diaz-Mitoma F et al. Oral famciclovir for the suppression of recurrent genital herpes. J Am Med Assoc
1998;280:887-92.
22A.16 Benedetti JK et al. Clinical re-activation of genital herpes simplex virus infection decreases in frequency
over time. Ann Intern Med 1999;131:14-20.
22A.17 Celum CL et al. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral
therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 2005;191(suppl. 1):
S107-14.
22A.18 Barton S et al. The role of anti-HSV therapeutics in the HIV infected host and in controlling the HIV
epidemic. Herpes 2005;12:15-22.
22A.19 Committee on Infectious Diseases of the American Academy of Pediatrics. Antiviral therapy and prophylaxis
for influenza in children. Pediatrics 2007;119:852-60.
22A.20 Hota S et al. Antivirals and the control of influenza outbreaks. Clin Infect Dis 2007;45:1362-8.
22A.21 Committee on Infectious Diseases of the American Academy of Pediatrics. Recommendations for
prevention and control of influenza in children, 2010-2011. Pediatrics 2010;126:816-26.
22A.22 Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines.
Morb Mortal Wkly Rep 2010;59(RR-8):1-62.
22A.23 Monto AS et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A
and B within households. J Infect Dis 2002;186:1582-8.
22A.24 Nicoll A et al. Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation
and potential implications. Euro Surveill 2008;13.
22A.25 Atkins JT et al. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus immunoglobulin
intravenous among preterm infants of thirty two weeks gestation and less: reduction in incidence,
severity of illness and cost. Pediatr Infect Dis J 2000;19:138-43.
22A.26 Committee on Infectious Diseases of the American Academy of Pediatrics. Modified recommendations
for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;
124:1694-701.
22A.27 Feltes TF et al. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients
with congenital heart disease. Expert Opin Biol Ther 2007;7:1471-80.
22A.28 Fenton C et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus
infection. Pediatr Drugs 2004;6:177-97.
22A.29 Centers for Disease Control and Prevention (CDC). Prevention of varicella. Morb Mortal Wkly Rep
2007;56(RR-4):1-40.
22A.30 Hambleton S et al. Preventing varicella-zoster disease. Clin Microbiol Rev 2005;18:70-80.
22A.31 Watson B et al. Postexposure effectiveness of varicella vaccine. Pediatrics 2000;105:84-8.
22A.32 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of oppor-